Cannabidivarin/cannabigerolic acid - CNBX Pharmaceuticals
Alternative Names: Cannabigerolic acid/Cannabidivarin; CBDV/CBGA; CBGA/CBDVLatest Information Update: 28 May 2024
At a glance
- Originator Cannabics Pharmaceuticals
- Developer CNBX Pharmaceuticals
- Class Antineoplastics; Cannabinoids; Small molecules
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Gastrointestinal cancer
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Colorectal-cancer in Israel
- 28 May 2024 No recent reports of development identified for preclinical development in Gastrointestinal-cancer in Israel
- 13 Oct 2022 CNBX Pharmaceuticals files for patent protection with US Patent and Trademark Office (USPTO) and with the Israel Patent Office for “Composition and method for treating cancer with cannabinoids” in US and Israel